Skip to Content
PR Newswire

Scientific Industries Announces Appointment of Dr. Jürgen Schumacher to the Board of Directors

Scientific Industries Announces Appointment of Dr. Jürgen Schumacher to the Board of Directors

Scientific Industries Announces Appointment of Dr. Jürgen Schumacher to the Board of Directors

PR Newswire

BOHEMIA, N.Y. and PITTSBURGH, April 30, 2021

BOHEMIA, N.Y. and PITTSBURGH, April 30, 2021 /PRNewswire/ -- Scientific Industries, Inc. (OTCQB: SCND) today announced the appointment of Dr. Jürgen Schumacher to the Company's Board of Directors.

Dr. Jürgen Schumacher is an internationally recognized German entrepreneur with more than 35 years of expertise in the biotech industry. Dr. Schumacher co-founded Qiagen AG, one of Germany's largest biotechnology companies, NewLab Bioquality AG, which was acquired by Charles River Laboratories International Inc., BiBiTech and Algiax Pharmaceuticals.  Dr. Schumacher advises and invests in promising biotech business models.

Dr. Schumacher holds a PhD in Biology from Heinrich Heine University of Düsseldorf and a Diploma in Biology from Technical University of Darmstadt.

John Moore, Chairman of Scientific Industries and President of Scientific Bioprocessing, Inc. (SBI), said, "We are delighted to welcome Dr. Schumacher as director on Scientific Industries' Board. Jürgen has built a distinguished career within the biotechnology industry and his extensive industry knowledge and experience will be a real asset to the Board. We look forward to working with him in the successful combination of aquila biolabs and Scientific Bioprocessing to create a new digital platform that brings dramatic innovation to bioprocessing and significantly enhances accuracy for improved time-to-market."

About Scientific Bioprocessing, Inc. (SBI)
SBI is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries, Inc.  To learn more, visit www.scientificbio.com.

About Scientific Industries, Inc.
Scientific Industries (OTCQB:SCND),  is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems and methods. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com.

Safe Harbor Statement
Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K.

Contact:
Sandy Williams
Marketing and Product Manager
Scientific Bioprocessing, Inc.
412-230-8463
media@scientificbio.com
www.scientificbio.com

Investor Contact:
Joe Dorame
Lytham Partners, LLC
Phone: (602) 889-9700
SCND@lythampartners.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/scientific-industries-announces-appointment-of-dr-jurgen-schumacher-to-the-board-of-directors-301280922.html

SOURCE Scientific Industries, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.